Fisher & Paykel HealthcareFSPKF +9.59%90 Return-on-Tangible-Equity is 25.79% as of Mar. 2026, which is 0% below its 10-year median of 25.81. GuruFocus rates FSPKF with a GF Score™ of 90/100 and a GF Value™ of $27.43 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 86.28% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Fisher & Paykel Healthcare's annualized net income for the quarter that ended in Mar. 2026 was $299 Mil. Fisher & Paykel Healthcare's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $1,159 Mil. Therefore, Fisher & Paykel Healthcare's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 25.79%.
The historical rank and industry rank for Fisher & Paykel Healthcare's Return-on-Tangible-Equity or its related term are showing as below:
FSPKF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.94 Med: 25.81 Max: 44.79
Current: 24.4
During the past 13 years, Fisher & Paykel Healthcare's highest Return-on-Tangible-Equity was 44.79%. The lowest was 7.94%. And the median was 25.81%.
FSPKF's Return-on-Tangible-Equity is ranked better than 86.28% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs FSPKF: 24.40
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Fisher & Paykel Healthcare Return-on-Tangible-Equity Related Terms
Fisher & Paykel Healthcare Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FSPKF vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 25.79% mean?
Fisher & Paykel Healthcare (FSPKF) has a Return-on-Tangible-Equity of 25.79% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 25.81. Over the past decade, Fisher & Paykel Healthcare's Return-on-Tangible-Equity has ranged from 7.94 to 44.79. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #104 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 13.7%.
Is Fisher & Paykel Healthcare's Return-on-Tangible-Equity too high?
Fisher & Paykel Healthcare's current Return-on-Tangible-Equity of 25.79% is near median its 10-year median of 25.81. Over the past 10 years, this metric has ranged from a low of 7.94 to a high of 44.79. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Fisher & Paykel Healthcare's value of 25.79% is 532.1% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #104 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #104 out of 758 companies for Return-on-Tangible-Equity. This places Fisher & Paykel Healthcare in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.08. Fisher & Paykel Healthcare's value of 25.79% is 532.1% above this benchmark. Historically, Fisher & Paykel Healthcare's own Return-on-Tangible-Equity has ranged from 7.94 to 44.79 over the past decade. While the company's 10-year median is 25.81 vs. the industry median of 4.08, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current Return-on-Tangible-Equity of 25.79% is 532.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current Return-on-Tangible-Equity is 25.79%, which is near median its own 10-year median of 25.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (FSPKF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.43, compared to a current price of $22.52 — trading 17.9% below its estimated fair value. The current Return-on-Tangible-Equity is 25.79%, which is near median its 10-year median of 25.81 and 532.1% above the Medical Devices & Instruments industry median of 4.08. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FSPKF), the current Return-on-Tangible-Equity is 25.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (FSPKF) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of $22.52 is trading 17.9% below its estimated GF Value™ of $27.43.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for FSPKF:
Return-on-Tangible-Equity: 25.79% (near median its 10-year median of 25.81)
GF Value™: $27.43 vs. price of $22.52 (17.9% below fair value)
Industry Position: 532.1% above the Medical Devices & Instruments median (#104 of 758)
No single metric tells the full story. See the FSPKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score
Get the complete analysis for FSPKF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSPKF has been successfully added to your 
